Clinical trials: HIV-infection/AIDS
HIV Infection, Liver Failure
Raltegravir in Patients With End Stage Liver Disease and in Transplant Recipients
This phase I/II, multi-center study is designed to determine the pharmacokinetic profile of Raltegravir in patients with end stage liver disease and to assess drug-drug interaction when Raltegravir is combined with…
- Conditions
- HIV Infection, Liver Failure, Evidence of Liver Transplantation
- Trial name
- LIVERAL (NCT01022476)
- Testing
- Raltegravir potassium
- Where
- France
- Volunteers
- 14 people
- Sponsor
- ANRS, Emerging Infectious Diseases
Pneumonia, Pneumocystis Carinii, HIV Infections
A Study of Three Drugs Plus Zidovudine in the Prevention of Infections in HIV-Infected Patients
To evaluate and compare 3 anti-pneumocystis regimens plus zidovudine (AZT) in persons with HIV infection and T4 cell count less than 200 cells/mm3.
- Trial name
- NCT00000991
- Testing
- Pentamidine isethionate, Sulfamethoxazole-Trimethoprim, Dapsone
- Where
- 21 sites in United States, Tanzania
- Volunteers
- 600 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
ARVs to Prevent Breastmilk HIV:Viral and Immune Responses
Identifying new approaches for preventing breastmilk transmission of HIV-1 is an important research priority. To this end, clinical trials are underway to evaluate the efficacy of HAART (zidovudine, lamivudine, nevirapine) during…
- Trial name
- NCT00167674
- Testing
- Combined short-course zidovudine/nevirapine, HAART
- Where
- Kenya
- Volunteers
- 58 people
- Sponsor
- University of Washington
HIV/AIDS
MyPEEPS Mobile Plus: A Multi-Level HIV Prevention Intervention for Young MSM
MyPEEPS Mobile Plus, a multi-level intervention for improving HIV prevention outcomes in YMSM, is a novel and evidence-driven approach using mobile technology to deliver HIV prevention information specifically developed for YMSM.
- Trial name
- NCT06741618
- Testing
- MyPEEPS Mobile, Electronic PrEP peer navigation
- Where
- United States
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Columbia University
HIV Infections
Phase II/III Study Evaluating the Effect of IL-2 on Preservation of the CD4 T-Lymphocytes After Interruption of Antiretroviral Treatment in HIV-Infected Patients With CD4 T-Lymphocyte Count Greater Than 500 Cells/mm3 Who Received Antiretroviral Tx
This study will examine whether interleukin-2 (IL-2) given before the interruption of antiretroviral (ARV) treatment could significantly extend the period of time that a patient is temporarily not taking ARV treatment and also…
- Trial name
- ILIADE (NCT00071890)
- Testing
- Interleukin 2, HAART, Treatment interruption
- Where
- 2 sites in United States, France
- Volunteers
- 148 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
Safety and Immunogenicity Study of SeV-G(NP) HIV Vaccine Administered Intranasally and Ad35-GRIN HIV Vaccine Given Intramuscularly in Prime-Boost Regimens in HIV-Uninfected Volunteers
The purpose of this study is to evaluate the safety, tolerability and immunogenicity of Sendai HIV vaccine SeV-G(NP) given intranasally and Ad35-GRIN administered intramuscularly in prime-boost regimens in HIV-uninfected, healthy…
- Trial name
- NCT01705990
- Testing
- SeV-G(NP) (0.2mL, 2x10^7 CIU), SeV-G(NP) (0.2mL, 2x10^8 CIU), Ad35-GRIN (0.5mL)
- Where
- 3 sites in Kenya, Rwanda and 1 more
- Volunteers
- 65 people, healthy volunteers welcome
- Sponsor
- International AIDS Vaccine Initiative
HIV Infection, Infection, Human Immunodeficiency Virus
KALETRA Or LEXIVA With Ritonavir Combined With EPIVIR And Abacavir In Naive Subjects Over 48 Weeks
This study will compare the ability of fosamprenavir 700 mg with ritonavir 100 mg twice a day or lopinavir 400 mg with ritonavir 100 mg twice a day both combined with a fixed dose combination tablet of abacavir 600 mg and…
- Trial name
- NCT00085943
- Testing
- LEXIVA (GW433908), Ritonavir, KALETRA
- Where
- 119 sites in United States, Austria and 12 more
- Volunteers
- 866 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
HIV Infection, Malignant Neoplasm
Factors Affecting Patient Participation in AIDS Malignancy Clinical Trials Consortium Clinical Trials
This pilot research trial studies factors affecting patient participation in Acquired Immune Deficiency Syndrome (AIDS) Malignancy Clinical Trials Consortium clinical trials.
- Conditions
- HIV Infection, Malignant Neoplasm, Precancerous Condition
- Trial name
- NCT01946217
- Testing
- questionnaire administration
- Where
- 14 sites in United States
- Volunteers
- 82 people
- Sponsor
- AIDS Malignancy Consortium
HIV Infections
Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy
IMPAACT P1026s is a Phase IV prospective clinical study to evaluate the pharmacokinetics (PKs) of antiretroviral (ARV) and tuberculosis (TB) medications in pregnant women and their infants.
- Trial name
- NCT00042289
- Testing
- atazanavir/cobicistat, darunavir/ritonavir dosage #1, darunavir/ritonavir dosage #2
- Where
- 62 sites in United States, Argentina and 6 more
- Volunteers
- 1,578 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
COVID-19 Prevalence in HIV-infected Patients
North-east area of France was hit in February 2020 by the new coronavirus disease, more severely than other French regions. Factors affecting the evolution of the disease and its severity have been quickly identified, among them…
- Trial name
- SeCoVIHA (NCT04515225)
- Testing
- Blood Sample
- Where
- France
- Volunteers
- 500 people
- Sponsor
- University Hospital, Strasbourg, France
HIV Infections
Growth Hormone to Increase Immune Function in People With HIV
Growth hormone plays an important role in the development of the immune system. Studies suggest that growth hormone may promote growth of the thymus, a gland responsible for the production of important immune cells called T…
- Trial name
- NCT00071240
- Testing
- Somatropin (recombinant human growth hormone)
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
FOTO: Five Consecutive Days on Treatment With Efavirenz, Tenofovir, and Emtricitabine Followed by Two Days Off Treatment Versus Continuous Treatment
For people with HIV who are currently taking specific medications (including Sustiva (efavirenz)) and have no detectable viral load, this study tracks how patients do if they take their medications for five days of the week…
- Trial name
- NCT00414635
- Testing
- Intermitent Dosing
- Where
- 7 sites in United States
- Volunteers
- 60 people
- Sponsor
- Community Research Initiative of New England
Influenza
Immunogenicity of Influenza Vaccines in HIV-infected Persons in Thailand
This study will assess the efficacy of a new intradermal formulation of the trivalent inactivated influenza vaccine compared to the standard intramuscular vaccine in HIV-infected men who have sex with men in Bangkok, Thailand.
- Trial name
- NCT01538940
- Testing
- Intradermal vaccine, Intramuscular vaccine
- Where
- Thailand
- Volunteers
- 415 people, healthy volunteers welcome
- Sponsor
- Centers for Disease Control and Prevention
HIV Infections
Effect of Anti-HIV Therapy (HAART) on HIV Levels in the Lungs and on Lung Cell Inflammation in HIV-Infected Patients
The purpose of this study is to see: (1) how the amount of HIV in the lungs compares to that in the blood; (2) if HAART reduces the amount of HIV in the lungs; and (3) if HAART reduces lung inflammation in HIV-infected patients.
- Trial name
- NCT00001110
- Testing
- Bronchoalveolar lavage
- Where
- 5 sites in United States, Puerto Rico
- Volunteers
- 50 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Sexually Transmitted Diseases, Disease Transmission, Infectious
Eban II: Intervention for HIV Sero-Discordant Couples
This study focuses on the implementation of an evidence-based HIV risk reduction intervention for HIV-serodiscordant, heterosexual African American couples ("Eban II") in two geographic areas (Northern and Southern California …
- Conditions
- Sexually Transmitted Diseases, Disease Transmission, Infectious, Safe Sex, HIV
- Trial name
- NCT01829282
- Testing
- Risk Reduction
- Where
- 8 sites in United States
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- University of California, Los Angeles
HIV-1-infection
Second-line Switch to Dolutegravir Study
Kenya has the 4th largest HIV burden in the world with about 1.6 million people living with HIV. Of these, just over 1 million are on antiretroviral therapy (ART).
- Trial name
- 2SD (NCT04229290)
- Testing
- Dolutegravir
- Where
- 4 sites in Kenya
- Volunteers
- 795 people
- Sponsor
- University of Nairobi
HIV Infections
Viral Dynamics and Pharmacokinetics of Abacavir and Tenofovir
Once-daily nucleotide/nucleoside reverse transcriptase inhibitor (NtRTI/NRTI) combinations form the backbone of many regimens. Although efficacy data exists between tenofovir and the pyrimidine analogues (i.e.
- Trial name
- NCT00214890
- Testing
- Tenofovir, Abacavir
- Where
- 5 sites in United States
- Volunteers
- 21 people
- Sponsor
- University of California, San Diego
HCV, HIV
KP-Led Same Day HCV Test and Treat Study
This is a Hybrid design to primarily assess effectiveness, and to secondarily observe and collect data on the implementation of the service.
- Trial name
- 479/65 (NCT05479760)
- Testing
- KP-Led HCV test and treat service
- Where
- 4 sites in Thailand
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Institute of HIV Research and Innovation Foundation, Thailand
HIV Infections
A Phase I/II Clinical Study of Nystatin I.V. (Intravenous) in Patients With HIV Infection.
To evaluate the clinical toxicity, safety, and maximum tolerated dose (MTD) of intravenous nystatin in patients with HIV infection. To evaluate the potential anti-HIV activity and clinical pharmacology of intravenous nystatin.
- Trial name
- NCT00002097
- Testing
- Nystatin
- Where
- United States
- Sponsor
- Argus Pharmaceuticals
HIV Infections, Substance Use
Reducing HIV: Safer Sex Skill Building in Pregnant Drug Abusing Women
This study will examine safer sex skills building (SSB), a targeted behavioral HIV prevention and risk reduction group intervention in two samples of pregnant drug abusing women.
- Trial name
- NCT00619320
- Testing
- Safer Sex Skills Building (SSB)
- Where
- 2 sites in United States
- Volunteers
- 380 people, healthy volunteers welcome
- Sponsor
- Virginia Commonwealth University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.